2008 (v1)
Publication
No description
Uploaded on: March 25, 2023
-
-
2011 (v1)Publication
At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February...
Uploaded on: April 14, 2023